Diabetes
Refine Search
Pharmaceutical
Danish diabetes care giant Novo Nordisk has launched Xultophy (IDegLira) for people with type 2 diabetes in Switzerland. 19 January 2015
Pharmaceutical
The type 2 diabetes treatment market in Asia-Pacific (APAC) region will rise in value from an estimated $6.5 billion in 2013 to $10.5 billion by 2020, representing a modest compound annual growth rate (CAGR) of 7.1%. 6 January 2015
Biotechnology
US clinical stage firm NephroGenex says it has successfully completed a thorough QT/QTc (TQT) cardiac safety study on Pyridorin (pyridoxamine dihydrochloride), a Phase III drug candidate for diabetic nephropathy. 31 December 2014
Biotechnology
US pharma major Eli Lilly and French biotech firm Adocia have entered into a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes. 19 December 2014
Pharmaceutical
France-based drug developer Poxel says that imeglimin, a novel compound in development to treat type 2 diabetes, demonstrated dose-dependent efficacy on two key measures of diabetes control in a Phase IIb trial conducted in both treatment-naïve patients and patients previously treated with a diabetes monotherapy. 17 December 2014
Pharmaceutical
The Alzheimer's Drug Discovery Foundation (ADDF) and the Alzheimer's Society UK announced new funding to explore the possibility of using a commonly prescribed drug which treats erectile dysfunction as the next treatment for dementia. 12 December 2014
Pharmaceutical
With respect to the treatment of type 2 diabetes in China, patient access to premium-priced agents is impeded as not all patients can afford these drugs, according to new research findings. 5 December 2014
Pharmaceutical
US drug major Eli Lilly has received approval from the European Commission for its GLP-1 receptor agonist Trulicity (dulaglutide) for the improvement of glycemic control in adult type 2 diabetes. 26 November 2014
Pharmaceutical
US pharma giant Merck & Co has submitted a new drug application for omarigliptin, its investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes, in Japan. 25 November 2014
Pharmaceutical
The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for Victoza (liraglutide), manufactured by Danish insulin giant Novo Nordisk, in the treatment of adult type 2 diabetes with moderate renal impairment. 21 November 2014
Pharmaceutical
French pharma major Sanofi is today outlining its intention to launch high-potential new medicines and vaccines that could result in up to 18 new launches for the company between 2014-2020, at an IR Thematic Seminar on New Medicines in Boston, USA. 20 November 2014
Pharmaceutical
Patients in Britain with diabetes are missing out on vital prescriptions that let them keep tabs on their condition, despite repeated warnings, says Diabetes UK. 19 November 2014
Pharmaceutical
Following an examination as to whether Jardiance (empagliflozin) offers an added benefit over appropriate comparator therapies, the German health cost advisory agency, the Institute for Quality and Efficiency in Health Care (IQWiG) has concluded that an added benefit was not proven. 19 November 2014
Pharmaceutical
The International Diabetes Federation has published its sixth Diabetes Atlas with a particular focus on the Middle East and North Africa. 14 November 2014
Pharmaceutical
The Scottish Medicines Consortium (SMC) has accepted German drugmaker Bayer’s Eylea (aflibercept solution for injection) for restricted use within NHS Scotland for the treatment of visual impairment due to diabetic macular oedema. 13 November 2014
Biotechnology
USA-based biotech firm Intarcia Therapeutics has started a strategic partnership with French independent drugmaker Servier outside the USA and Japan, to develop and commercialize ITCA 650 (exenatide), Intarcia's Phase III investigational therapy for the treatment of type 2 diabetes. 12 November 2014
Pharmaceutical
Positive new data from the Phase IIIa SCALE Obesity and Prediabetes trial were presented today at Obesity Week 2014, the 2nd Annual Congress of The American Society for Metabolic and Bariatric Surgery and The Obesity Society. 4 November 2014
Pharmaceutical
Danish diabetes care giant Novo Nordisk has today launched NovoRapid PumpCart, the first pre-filled pump cartridge with an insulin analogue that has been specifically designed for insulin pumps. 3 November 2014
Pharmaceutical
Danish insulin giant Novo Nordisk has made a 750 million Danish kroner ($130 million) investment in new laboratories at the company’s research and development campus. 31 October 2014
Pharmaceutical
The US Food and Drug Administration has approved Anglo-Swedish pharma major AstraZeneca’s once-daily Xigduo XR (dapagliflozin and metformin hydrochloride extended-release) for the treatment of adults with type 2 diabetes. 30 October 2014
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze